Saturday 17 October 2026
Export ZVSA’s income statement to Excel — free account
ZyVersa Therapeutics, Inc.
ZVSA Healthcare Biotechnology
In the quarter to March 2026, EPS grew 69.9% and free cash flow grew 54.9%, each against the same quarter a year earlier.
0.05
0.00
0.00%
Follow ZVSA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 483.00 | 6.75 | 0.98 | 0.11 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 8,750.00 | 1,533.00 | 25.00 | 1.95 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 7 | 7 | 7 | 6 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | — | (13) | (8) | (15) | (108) | (9) | (26) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | (13) | (8) | (14) | (98) | (9) | (25) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 12 | 0 | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (27.24) | (116.96) | (518.57) | (1,089.70) | (8.48) | (4.18) | |||||
| Cash flow | — | — | — | — | (11.28) | (73.46) | (189.48) | (89.44) | (6.77) | (0.86) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | (11.28) | (73.46) | (189.48) | (89.44) | (6.77) | (0.86) | |||||
| Book value | — | — | — | — | (18.38) | (185.69) | 3,862.91 | 113.59 | 7.67 | (2.08) | |||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 0 | 1 | 6 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (5) | (5) | (5) | (9) | (8) | (5) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | (5) | (5) | (5) | (9) | (8) | (5) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (7) | (13) | (2) | (7) | (10) | (12) | ||||
| Total debt | — | — | — | — | 4 | 9 | 0 | — | — | — | |||||
| Net debt | — | — | — | — | 4 | 0 | (6) | (3) | (2) | 0 | |||||
| Shareholders’ equity | — | — | — | — | (9) | (13) | 100 | 11 | 9 | (12) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (3,699.88) | (892.39) | (40.35) | (151.11) | (44.08) | (238.24) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (9.22) | (848.52) | (81.75) | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | 74.44 | (55.60) | (191.89) | (96.10) | 1,289.40 | |||||
Negative figures in brackets.
Charts ten years each
ZyVersa Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SPRC SciSparc Ltd. | $1.2M | — (loss-making) | 7.9× | — | n/m | +14.95% (above 0%: growing) | 35.75% | 0.00% | Compare |
| CYTOF Altamira Therapeutics Ltd. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +85.35% (above 0%: growing) | (157.79%) | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | −12.97% (below 0%: shrinking) | — | 0.00% | Compare |
| BPTH Bio-Path Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +98.68% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CRIS Curis, Inc. | $1.1M | — (loss-making) | — (loss-making) | −65.98% (below 0%: shrinking) | n/m | −20.44% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MNTRQ 9 Meters Biopharma, Inc. | $1.0M | — (loss-making) | — | −25.99% (below 0%: shrinking) | n/m | +0.01% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ZVSA ZyVersa Therapeutics, Inc. | $970.0K | — (loss-making) | — | — | n/m | +54.91% (above 0%: growing) | 0.00% | 0.00% | |
| LYRA Lyra Therapeutics, Inc. | $870.0K | — (loss-making) | — (loss-making) | −96.65% (below 0%: shrinking) | n/m | +45.44% (above 0%: growing) | 100.00% | (101,685.71%) | Compare |
| BTTX Better Therapeutics, Inc. | $850.0K | — (loss-making) | — | — | n/m | +20.43% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $1.1M | — | — | −65.98% | — | +17.69% | 0.00% | 0.00% |
ZyVersa Therapeutics, Inc. (ZVSA) key facts
- ZyVersa Therapeutics, Inc. (ZVSA) is a Biotechnology company in the Healthcare sector.
- As of October 15, 2026, ZVSA traded at $0.05, a market capitalization of $970,000.00.
- Return on equity was 1,289.4% and debt-to-equity 0.00.
ZyVersa Therapeutics, Inc. (ZVSA) Latest News
No news at this impact. Lower the threshold for more.